Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy

Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy

Background: Immune checkpoint inhibitors (ICIs) targeting PD-1 or PD-L1 improved the survival of non-small cell lung cancer (NSCLC) patients with PD-L1 expression ≥50% and without alterations in EGFR, ALK, ROS1, RET. However, markers able to predict the efficacy of ICIs, in combination with PD-L1 ex...

Full description

Bibliographic Details
Main Authors: Marco Cefalì, Samantha Epistolio, Giulia Ramelli, Dylan Mangan, Francesca Molinari, Vittoria Martin, Stefania Freguia, Luca Mazzucchelli, Patrizia Froesch, Milo Frattini, Luciano Wannesson
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Journal of Clinical Medicine
Subjects:
KRAS mutation
immune checkpoint inhibitor (ICI)
progression-free survival (PFS)
overall survival (OS)
non-small cell lung cancer (NSCLC)
PD-L1
Online Access:https://www.mdpi.com/2077-0383/11/6/1627

Internet

https://www.mdpi.com/2077-0383/11/6/1627

Similar Items